查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1992818

感染疾病物市场：2026-2032年全球市场预测（依产品类型、适应症、给药途径、通路和最终用户划分）

Anti-infectives Market by Product Type, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，感染疾病物市场价值将达到 1,383.7 亿美元，到 2026 年将成长至 1,463 亿美元，到 2032 年将达到 1997.3 亿美元，复合年增长率为 5.38%。

主要市场统计数据
基准年 2025 1383.7亿美元
预计年份：2026年 1463亿美元
预测年份 2032 1997.3亿美元
复合年增长率 (%) 5.38%

为感染疾病物市场制定一个综合框架，以明确策略决策者在临床、营运、监管和创新方面的优先事项。

感染疾病物领域处于紧迫的公共卫生需求与复杂的商业性动态的交汇点，临床需求与供应链现实和快速发展的科学技术之间存在衝突。本文透过建立影响产业、医疗服务提供者和政策制定者决策的关键主题支柱，系统地梳理了这种交汇点。治疗方法，并透过总结决定短期优先事项的结构性、临床和监管因素，引导读者阅读以下章节。

快速诊断、新型治疗方法和具有韧性的供应链策略如何重塑感染疾病物领域的临床决策和商业模式。

抗感染疾病医学领域正经历一场变革性的重塑，这场变革涵盖科学、商业性和製度等多个层面。精准诊断和快速分子检测技术的进步使得更早期、更有针对性的治疗方法成为可能，从而改变了处方模式和对特定药物类别的需求。同时，创新正从渐进式改进加速发展到新型治疗方法和基于机制的策略，以应对抗药性病原体，并在生物製药公司、诊断开发商和临床网路之间催生出新的伙伴关係模式。因此，价值链正从以产品为中心的模式演变为提供整合治疗、诊断、合理用药方案和数位化监测平台的综合治疗方法。

评估到 2025 年累积关税调整对抗感染疾病药物整个价值链的筹资策略、业务永续营运和投资决策的重大影响。

到2025年，累积贸易政策措施和关税调整正在影响整个感染疾病物供应链的成本结构和策略规划，尤其是那些依赖跨境采购中间体和成品的公司。虽然关税政策并非对所有治疗领域都一视同仁，但其累积影响正在提高人们对单一供应商脆弱性的认识，并加速减少对地理位置集中供应商依赖的步伐。因此，采购团队和生产主管越来越重视供应商多元化、建立本地生产能力以及透过合约保障措施来应对关税相关的不确定性。

综合細項分析揭示治疗领域、临床适应症、给药途径、通路和差异化策略对最终使用者的影响。

一套精细的细分框架揭示了临床需求、产品特性和分销管道动态相互作用，从而形成差异化策略重点的领域。基于产品类型，该领域涵盖了广泛的分类，包括抗生素、抗真菌药物、抗寄生虫药物和抗病毒药物。在抗生素领域，策略重点领域包括Aminoglycosides、β-内酰胺类、Fluoroquinolones、大环内酯类、磺胺类药物和四环霉素，每种药物都有其独特的抗药性特征，并对合理用药产生影响。抗真菌药物领域包括Allylamines、Azole类、Echinocandins和Polyenes，这些药物在抗菌频谱、毒性特征以及是用于住院或门诊病人存在差异。抗寄生虫药包括驱虫药、抗疟疾药和抗原生动物药，区域流行病学影响需求模式。另一方面，抗病毒药物包括神经氨酸酶抑制剂、核苷类似物、聚合酵素抑制剂和蛋白酶抑制剂，这反映了其作用机制的多样性以及在慢性病和急性疾病中的应用。

区域比较趋势突显了流行病学、製造业生态系统、监管方法和医疗保健财务如何塑造不同的策略重点。

区域趋势塑造了美洲、欧洲、中东和非洲以及亚太地区的感染疾病物格局，将流行病学、生产能力、监管方法和支付方行为以独特的模式联繫起来。在美洲，医疗保健系统凭藉其先进的医院功能、大规模的门诊市场和成熟的学名药生产体系，既需要新的疗法，也需要优化的筹资策略来维持药物的可及性。在欧洲、中东和非洲，监管协调的努力与多样化的医疗保健资金筹措模式并存，并且高度重视合理使用抗菌药物，影响药物目录的选择和报销途径。

已成立的製药公司、非专利生产商、生物技术创新者和契约製造的策略行动和竞争定位将决定未来的主导。

在感染疾病物领域，各公司的发展轨迹正在分化。传统製药公司、学名药领导企业、生物技术创新者和契约製造采取差异化策略，以获取临床和商业性价值。大型成熟製药公司利用其广泛的产品组合、丰富的监管经验和全球分销网络，为后期临床项目提供支持，并维持关键产品的持续供应。同时，学名药生产商和专业化学品生产商是稳定供应的关键合作伙伴，他们专注于成本效益高的生产、活性成分的大规模生产以及对需求激增的快速反应。

产业领导者面临的实际策略挑战是，如何协调诊断、管理、灵活製造和循证合同，以建立永续优势。

产业领导者应优先采取一系列高影响力措施，以兼顾临床价值、业务永续营运和商业性可行性。首先，透过将快速诊断和合理用药方案与药物导入相结合，并确保新药和现有药物的有效和持续使用，从而维持药物的长期临床效用。其次，透过采购多元化和投资于生产柔软性，在保持成本竞争力的同时，降低地缘政治和关税相关风险。合约机制和策略伙伴关係可以加速这一转型。第三，与保险公司和医疗保健系统采用基于适应症和疗效的合约模式，以协调合理用药的奖励，并展现药物的实际价值。

为了检验这些见解，我们采用了一种稳健的混合方法研究途径，结合了初步访谈、监管和临床文献综述、案例研究和情境映射。

本分析的调查方法结合了多方面的证据、专家见解和结构化整合，旨在提供可操作的洞见。主要研究包括对製药、生物技术、製造和临床领域的管理人员进行深度访谈，并辅以与监管专家和供应链从业人员的咨询，以检验营运影响。次要研究则包括对同行评审文献、监管指导文件、临床治疗指南和公开的企业资讯披露进行系统性回顾，以阐明趋势并提供多方面的检验，从而对研究结果进行深入分析。

整合是平衡紧急復原措施与长期创新和管理优先事项的结论，旨在指导策略性投资和政策参与。

总之，在诊断技术进步、价值链需求演变以及创新模式策略转变的驱动下，感染疾病物产业正经历着一场深刻的变革。这些因素既带来了挑战，也带来了机会。挑战包括抗菌素抗药性的动态变化、日益复杂的采购流程以及政策的不确定性。另一方面，机会则包括整合诊断和治疗方案、建立稳健的生产伙伴关係关係以及将临床价值与支付结果相结合的新型商业模式。本文的分析阐明了应将资源集中投入哪些领域，以维持药物的可及性并提供差异化的治疗价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：感染疾病物市场：依产品类型划分

  • 抗生素
    • Aminoglycosides
    • β-内酰胺
    • Fluoroquinolones
    • 大环内酯类
    • 磺胺类药物
    • 四环霉素
  • 抗真菌药物
    • Allylamines
    • Azole
    • Echinocandins
    • Polyenes
  • 抗寄生虫药物
    • 驱虫
    • 抗疟疾药
    • 原生动物治疗药物
  • 抗病毒药物
    • 神经氨酸酶抑制剂
    • 核苷类似物
    • 聚合酵素抑制剂
    • 蛋白酶抑制剂

第九章：感染疾病物市场：依适应症划分

  • 血液感染疾病
  • 胃肠道感染疾病
  • 呼吸道感染疾病
    • 支气管炎
    • 社区型肺炎
    • 院内肺炎
  • 皮肤和软组织感染疾病
  • 尿道感染

第十章：感染疾病物市场：依给药途径划分

  • 吸入
  • 口服
  • 肠外
  • 外用

第十一章：感染疾病物市场：依分销管道划分

  • 在线的
  • 离线

第十二章：感染疾病物市场：依最终用户划分

  • 诊所
  • 居家照护设施
  • 医院

第十三章：感染疾病物市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：感染疾病物市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：感染疾病物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国感染疾病物市场

第十七章：中国感染疾病市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline plc（GSK）
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co Inc
  • Novartis AG
  • Otsuka Pharmaceutical Co Ltd
  • Pfizer Inc
  • Sanofi
  • Shionogi & Co Ltd
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc
  • Wockhardt Limited
  • Zydus Lifesciences Limited
Product Code: MRR-1A1A064C0031

The Anti-infectives Market was valued at USD 138.37 billion in 2025 and is projected to grow to USD 146.30 billion in 2026, with a CAGR of 5.38%, reaching USD 199.73 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 138.37 billion
Estimated Year [2026] USD 146.30 billion
Forecast Year [2032] USD 199.73 billion
CAGR (%) 5.38%

Comprehensive framing of the anti-infectives landscape to clarify clinical, operational, regulatory, and innovation priorities for strategic decision-makers

The anti-infectives domain stands at the intersection of urgent public health need and complex commercial dynamics, where clinical imperatives collide with supply chain realities and rapid scientific progress. This introduction frames that convergence by establishing the critical thematic pillars that shape decision-making across industry, healthcare providers, and policy sponsors. It highlights the dual challenge of addressing antimicrobial resistance while ensuring resilient access to established and novel therapies, and it orients readers toward the sections that follow by summarizing the structural, clinical, and regulatory forces that will determine near-term priorities.

In the current environment, stakeholders must balance short-term operational responses with mid- to long-term strategic investments. Accordingly, this section positions the narrative around four core dimensions: therapeutic innovation and repurposing, manufacturing and procurement resilience, regulatory and market access dynamics, and integrated diagnostic stewardship. These dimensions serve as the lenses through which subsequent analyses of segmentation, regional differences, company strategy, and policy impacts should be interpreted. By clarifying the interplay among scientific advances, distribution channels, and care settings, this introduction prepares leaders to translate evidence into prioritized action.

Finally, the introduction emphasizes evidence-driven decision-making and cross-sector collaboration as foundational principles. It underscores the necessity of linking clinical practice with supply chain design and market intelligence, thereby creating a consistent frame for the deeper insights and recommendations presented in the rest of the executive summary.

How rapid diagnostics, novel therapeutic modalities, and resilient supply chain strategies are reshaping clinical decision making and commercial models across anti-infectives

The anti-infectives landscape is being reshaped by transformative shifts that are simultaneously scientific, commercial, and systemic. Advances in precision diagnostics and rapid molecular testing are enabling earlier and more targeted therapeutic choices, which in turn alter prescribing patterns and demand for specific classes of agents. At the same time, innovation has accelerated beyond incremental modifications toward novel modalities and mechanism-based therapies that address resistant pathogens, creating new partnership models between biopharma, diagnostic developers, and clinical networks. As a result, value chains are evolving from product-centric models to integrated solution offerings that combine therapeutics with diagnostics, stewardship programs, and digital monitoring platforms.

Concurrently, supply chain strategies are undergoing structural rebalancing. Stakeholders are increasingly prioritizing manufacturing flexibility, dual sourcing of critical active pharmaceutical ingredients, and strategic inventory policies to mitigate geopolitical and logistics risks. Regulatory environments are adapting to these shifts through expedited pathways for clinically urgent agents and greater emphasis on real-world evidence to support treatment decisions. Market access pressures are also stimulating new contracting approaches, including indication-specific agreements and outcome-based pricing that align incentives for appropriate use.

Taken together, these transformational changes are creating opportunities for nimble organizations to differentiate through integrated offerings, durable manufacturing strategies, and closer alignment with clinical workflows. The net effect is a more interconnected ecosystem in which scientific innovation, operational resilience, and data-driven market access strategies determine competitive positioning and public health impact.

Assessment of how cumulative tariff adjustments through 2025 have materially influenced sourcing strategies, operational resilience, and investment decisions across the anti-infectives value chain

Cumulative trade policy measures and tariff adjustments enacted through 2025 have influenced cost structures and strategic planning across the anti-infectives supply chain, particularly for firms reliant on cross-border sourcing of intermediates and finished products. While tariff policy does not uniformly apply to all therapeutic categories, its cumulative effect has been to raise awareness of single-source vulnerabilities and to accelerate initiatives that reduce dependence on geographically concentrated suppliers. Consequently, procurement teams and manufacturing executives have increasingly prioritized supplier diversification, localized capacity building, and contractual protections to manage tariff-driven uncertainty.

Moreover, tariff-related pressures have shifted the calculus for capital investment and partnership formation. Companies evaluating new manufacturing sites or expansion projects must now weigh potential tariff exposure alongside labor, regulatory, and logistics considerations. At the same time, some firms have pursued strategic vertical integration or established closer contractual relationships with contract development and manufacturing organizations to buffer against external trade shocks. These responses reflect an operational pivot toward resilience rather than solely cost minimization.

Finally, regulatory and policy responses to tariff pressures have introduced additional considerations. In many jurisdictions, policymakers have shown a willingness to implement targeted exemptions or engagement programs to preserve access to essential medicines, which has moderated some of the immediate impacts for critical items. Nevertheless, the cumulative impact through 2025 remains a material factor in procurement strategy, supply chain design, and financial planning across the anti-infectives ecosystem, prompting sustained emphasis on scenario planning and adaptive sourcing frameworks.

Integrated segmentation analysis revealing therapeutic classes, clinical indications, administration routes, distribution channels, and end-user implications for differentiated strategy

A nuanced segmentation framework illuminates where clinical need, product characteristics, and channel dynamics interact to create differentiated strategic priorities. Based on product type, the field spans broad classes such as antibiotics, antifungals, antiparasitics, and antivirals; within antibiotics, strategic focus areas include aminoglycosides, beta-lactams, fluoroquinolones, macrolides, sulfonamides, and tetracyclines, each with distinct resistance profiles and stewardship implications. The antifungal segment includes allylamines, azoles, echinocandins, and polyenes, which vary by spectrum of activity, toxicity profiles, and inpatient versus outpatient application. Antiparasitics cover anthelmintics, antimalarials, and antiprotozoals, with regional epidemiology driving demand patterns, while antivirals encompass neuraminidase inhibitors, nucleoside analogues, polymerase inhibitors, and protease inhibitors, reflecting diverse mechanisms and both chronic and acute use cases.

Based on indication, the market separates along clinical presentations such as bloodstream infections, gastrointestinal infections, respiratory infections, skin and soft tissue infections, and urinary tract infections; respiratory infections further distinguish bronchitis, community-acquired pneumonia, and hospital-acquired pneumonia, each of which involves unique diagnostic pathways and settings of care. Based on route of administration, therapeutic choices are organized by inhalation, oral, parenteral, and topical delivery, which influence prescribing patterns, adherence considerations, and distribution logistics. Based on distribution channel, medicines are delivered through drug stores, hospital pharmacies, online pharmacies, and retail pharmacies, with each channel presenting different reimbursement dynamics and patient access considerations. Based on end user, adoption and purchasing behavior diverge across clinics, home care settings, and hospitals, shaping contracting strategies, clinical training needs, and point-of-care diagnostics integration.

Integrating these segmentation layers reveals priority intersections where development investment, commercial focus, and supply chain resilience yield the greatest strategic return. For example, agents intended for hospital-acquired respiratory infections that require parenteral administration will necessitate robust hospital pharmacy alignment and inpatient stewardship programs, whereas oral antivirals for outpatient care will prioritize retail and online pharmacy distribution, adherence solutions, and payer engagement.

Comparative regional dynamics highlighting how epidemiology, manufacturing ecosystems, regulatory approaches, and healthcare financing shape differentiated strategic priorities

Regional dynamics shape the anti-infectives environment by aligning epidemiology, manufacturing capacity, regulatory approaches, and payer behavior in distinct patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, health systems combine advanced hospital capabilities with large outpatient markets and established generics manufacturing, creating demand for both novel therapeutics and optimized procurement strategies that preserve access. Across Europe, Middle East & Africa, regulatory harmonization efforts coexist with varied healthcare financing models and a pronounced emphasis on antimicrobial stewardship, which influences formulary decisions and reimbursement pathways.

In the Asia-Pacific region, rapid expansion of manufacturing capacity, strong generics competitiveness, and shifting R&D investment are key features; these dynamics are coupled with heterogeneous regulatory systems and varying levels of healthcare infrastructure, which together drive both export-oriented production and growing regional demand for innovative treatments. Transitional economies within these regions are shaping procurement models that balance cost containment with the need to upgrade clinical diagnostics and supply chain resilience. Across all regions, cross-border collaboration on surveillance and resistance monitoring is increasingly important, and regional policy initiatives often determine priority access for specific therapeutic classes.

Taken together, these regional insights emphasize that strategies must be tailored to local regulatory norms, manufacturing ecosystems, and clinical practice patterns. Companies that align product formulation, distribution models, and stewardship partnerships to regional realities will be better positioned to achieve sustained clinical adoption and resilient supply operations.

Strategic behaviors and competitive positioning of established pharmaceutical firms, generics manufacturers, biotech innovators, and contract manufacturers shaping future leadership

Company trajectories within anti-infectives are diverging as traditional pharmaceutical firms, generics leaders, biotech innovators, and contract manufacturers adopt differentiated strategies to capture clinical and commercial value. Established large-pharma players are leveraging broad portfolios, regulatory experience, and global distribution networks to support late-stage clinical programs and to maintain supply continuity for essential lines. Conversely, generics manufacturers and specialized chemical producers are concentrating on cost-efficient production, scale in active pharmaceutical ingredients, and rapid response to demand spikes, making them pivotal partners for supply security.

Biotech and small-cap innovators are focusing on novel mechanisms of action, narrow-spectrum agents, and adjunctive therapies that enable more targeted approaches to resistant pathogens. These firms frequently engage in partnerships with diagnostic companies and clinical networks to demonstrate value through precision prescribing. Contract development and manufacturing organizations are expanding capabilities to offer flexible, small-batch production and regulatory support, thereby enabling faster commercialization for both emergent agents and reformulated legacy products. Across company types, M&A, licensing, and co-development agreements are being used strategically to bridge R&D gaps, secure manufacturing footprint, and accelerate access to complementary technologies.

In sum, competitive advantage is increasingly derived from the ability to integrate clinical differentiation with operational resilience and payer-aware commercial models. Firms that combine targeted innovation with supply chain agility and strong clinical evidence generation are positioned to lead, while those that lag in diagnostic integration or flexible manufacturing risk erosion of market relevance.

Practical strategic imperatives for industry leaders to align diagnostics, stewardship, flexible manufacturing, and evidence-based contracting for sustainable advantage

Industry leaders should prioritize a set of high-impact actions that align clinical value with operational resilience and commercial viability. First, integrate rapid diagnostics and stewardship programs with therapeutic rollouts to ensure that new and existing agents are used effectively and sustainably, thereby preserving long-term clinical utility. Second, diversify sourcing and invest in manufacturing flexibility to mitigate geopolitical and tariff-related risks while preserving cost competitiveness; contractual mechanisms and strategic partnerships can accelerate this transition. Third, adopt indication- and outcome-based contracting models with payers and health systems to align incentives for appropriate use and to demonstrate real-world value.

Further, invest selectively in novel mechanisms and platform technologies that address resistant pathogens, while leveraging strategic alliances for accelerated clinical development and market entry. Commit to comprehensive surveillance and data-sharing initiatives that support both public health objectives and commercial decision-making, enabling more precise targeting of clinical trials and post-market evidence generation. Finally, ensure organizational readiness through cross-functional governance that links R&D, regulatory affairs, supply chain, and commercial teams to expedite decision cycles and reduce time-to-clinic or time-to-market for priority assets.

By implementing these actions in a coordinated manner, leaders can balance short-term access imperatives with long-term stewardship and innovation goals, transforming systemic challenges into sources of competitive advantage.

Robust mixed-methods research approach combining primary interviews, regulatory and clinical literature review, case studies, and scenario mapping to validate insights

The research methodology underpinning this analysis combines multi-source evidence, expert input, and structured synthesis to deliver actionable insights. Primary research included in-depth interviews with senior executives across pharmaceutical, biotech, manufacturing, and clinical backgrounds, supplemented by consultations with regulatory specialists and supply chain practitioners to validate operational implications. Secondary research entailed systematic review of peer-reviewed literature, regulatory guidance documents, clinical treatment guidelines, and publicly available corporate disclosures to contextualize trends and triangulate findings.

Analytical approaches incorporated qualitative thematic analysis and scenario-based supply chain mapping to explore how policy changes, tariff dynamics, and clinical innovation could interact under alternative conditions. Case studies were used to illustrate best practices in manufacturing resilience, diagnostic-therapeutic integration, and stewardship program implementation. Finally, internal expert panels reviewed draft findings to ensure relevance for commercial strategy and to refine recommendations according to operational feasibility and regulatory realities.

This mixed-methods approach emphasizes transparency, triangulation, and practitioner validation, providing stakeholders with a robust evidence base for strategic planning without relying on proprietary forecasting that could obscure operational nuances.

Concluding synthesis that balances urgent resilience measures with long-term innovation and stewardship priorities to guide strategic investment and policy engagement

In conclusion, the anti-infectives sector is undergoing a period of substantive transformation driven by diagnostic advances, evolving supply chain imperatives, and strategic shifts in innovation models. These forces are creating both challenges and opportunities: challenges in the form of resistance dynamics, procurement complexity, and policy uncertainty; and opportunities in the form of integrated diagnostic-therapeutic solutions, resilient manufacturing partnerships, and novel commercial models that align clinical value with payment outcomes. The synthesis presented here highlights where to focus resources to preserve access and to deliver differentiated therapeutic value.

Organizations that proactively integrate stewardship with go-to-market strategies, diversify their manufacturing and sourcing footprint, and build evidence generation frameworks aligned with payer expectations will be best positioned to navigate the evolving landscape. Collaboration across public and private stakeholders, investment in flexible production capabilities, and commitment to targeted R&D will be essential to ensuring sustained patient access and long-term therapeutic effectiveness. The recommendations in this summary are designed to be operationally actionable and to support decision-makers as they translate insight into measurable strategic moves.

Ultimately, the path forward requires balancing near-term operational resilience with long-term investments in innovation and stewardship, ensuring that therapeutic advances are preserved and widely accessible for the populations that need them most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-infectives Market, by Product Type

  • 8.1. Antibiotics
    • 8.1.1. Aminoglycosides
    • 8.1.2. Beta Lactams
    • 8.1.3. Fluoroquinolones
    • 8.1.4. Macrolides
    • 8.1.5. Sulfonamides
    • 8.1.6. Tetracyclines
  • 8.2. Antifungals
    • 8.2.1. Allylamines
    • 8.2.2. Azoles
    • 8.2.3. Echinocandins
    • 8.2.4. Polyenes
  • 8.3. Antiparasitics
    • 8.3.1. Anthelmintics
    • 8.3.2. Antimalarials
    • 8.3.3. Antiprotozoals
  • 8.4. Antivirals
    • 8.4.1. Neuraminidase Inhibitors
    • 8.4.2. Nucleoside Analogues
    • 8.4.3. Polymerase Inhibitors
    • 8.4.4. Protease Inhibitors

9. Anti-infectives Market, by Indication

  • 9.1. Bloodstream Infections
  • 9.2. Gastrointestinal Infections
  • 9.3. Respiratory Infections
    • 9.3.1. Bronchitis
    • 9.3.2. Community Acquired Pneumonia
    • 9.3.3. Hospital Acquired Pneumonia
  • 9.4. Skin And Soft Tissue Infections
  • 9.5. Urinary Tract Infections

10. Anti-infectives Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Oral
  • 10.3. Parenteral
  • 10.4. Topical

11. Anti-infectives Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Anti-infectives Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care Settings
  • 12.3. Hospitals

13. Anti-infectives Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Anti-infectives Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anti-infectives Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Anti-infectives Market

17. China Anti-infectives Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc
  • 18.7. Astellas Pharma Inc
  • 18.8. AstraZeneca plc
  • 18.9. Aurobindo Pharma Limited
  • 18.10. Bayer AG
  • 18.11. Biocon Limited
  • 18.12. Boehringer Ingelheim GmbH
  • 18.13. Bristol Myers Squibb
  • 18.14. Cipla Limited
  • 18.15. Dr. Reddy's Laboratories Ltd
  • 18.16. Eli Lilly and Company
  • 18.17. F. Hoffmann-La Roche Ltd
  • 18.18. Gilead Sciences Inc
  • 18.19. GlaxoSmithKline plc (GSK)
  • 18.20. Glenmark Pharmaceuticals Limited
  • 18.21. Johnson & Johnson
  • 18.22. Lupin Limited
  • 18.23. Merck & Co Inc
  • 18.24. Novartis AG
  • 18.25. Otsuka Pharmaceutical Co Ltd
  • 18.26. Pfizer Inc
  • 18.27. Sanofi
  • 18.28. Shionogi & Co Ltd
  • 18.29. Sun Pharmaceutical Industries Limited
  • 18.30. Teva Pharmaceutical Industries Limited
  • 18.31. Viatris Inc
  • 18.32. Wockhardt Limited
  • 18.33. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-INFECTIVES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-INFECTIVES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ALLYLAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ALLYLAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ALLYLAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTHELMINTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIMALARIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIMALARIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIMALARIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPROTOZOALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPROTOZOALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIPROTOZOALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY POLYMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BLOODSTREAM INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BLOODSTREAM INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BLOODSTREAM INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BRONCHITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BRONCHITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY BRONCHITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. GCC ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. GCC ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. GCC ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 230. GCC ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 231. GCC ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 232. GCC ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 233. GCC ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. GCC ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 235. GCC ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. GCC ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. GCC ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. G7 ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. G7 ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. G7 ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 263. G7 ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 264. G7 ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 265. G7 ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 266. G7 ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 267. G7 ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 268. G7 ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. G7 ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. G7 ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. NATO ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. NATO ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 274. NATO ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 275. NATO ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 276. NATO ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 277. NATO ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 278. NATO ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 279. NATO ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. NATO ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. NATO ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL ANTI-INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA ANTI-INFECTIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA ANTI-INFECTIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA ANTI-INFECTIVES MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA ANTI-INFECTIVES MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA ANTI-INFECTIVES MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA ANTI-INFECTIVES MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA ANTI-INFECTIVES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA ANTI-INFECTIVES MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA ANTI-INFECTIVES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA ANTI-INFECTIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA ANTI-INFECTIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)